GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » Cash Flow from Financing

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Cash Flow from Financing : HK$-482 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2024, Yichang HEC ChangJiang Pharmaceutical Co paid HK$0 Mil more to buy back shares than it received from issuing new shares. It spent HK$131 Mil paying down its debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0 Mil from paying cash dividends to shareholders. It spent HK$60 Mil on other financial activities. In all, Yichang HEC ChangJiang Pharmaceutical Co spent HK$191 Mil on financial activities for the six months ended in Dec. 2024.


Yichang HEC ChangJiang Pharmaceutical Co Cash Flow from Financing Historical Data

The historical data trend for Yichang HEC ChangJiang Pharmaceutical Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yichang HEC ChangJiang Pharmaceutical Co Cash Flow from Financing Chart

Yichang HEC ChangJiang Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.62 229.56 -878.89 -1,615.40 -478.65

Yichang HEC ChangJiang Pharmaceutical Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -937.70 432.58 -2,047.98 -351.23 -130.32

Yichang HEC ChangJiang Pharmaceutical Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Yichang HEC ChangJiang Pharmaceutical Co's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Yichang HEC ChangJiang Pharmaceutical Co's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-482 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yichang HEC ChangJiang Pharmaceutical Co  (HKSE:01558) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Yichang HEC ChangJiang Pharmaceutical Co's issuance of stock for the six months ended in Dec. 2024 was HK$0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Yichang HEC ChangJiang Pharmaceutical Co's repurchase of stock for the six months ended in Dec. 2024 was HK$0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Yichang HEC ChangJiang Pharmaceutical Co's net issuance of debt for the six months ended in Dec. 2024 was HK$-131 Mil. Yichang HEC ChangJiang Pharmaceutical Co spent HK$131 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Yichang HEC ChangJiang Pharmaceutical Co's net issuance of preferred for the six months ended in Dec. 2024 was HK$0 Mil. Yichang HEC ChangJiang Pharmaceutical Co paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Yichang HEC ChangJiang Pharmaceutical Co's cash flow for dividends for the six months ended in Dec. 2024 was HK$0 Mil. Yichang HEC ChangJiang Pharmaceutical Co received HK$0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Yichang HEC ChangJiang Pharmaceutical Co's other financing for the six months ended in Dec. 2024 was HK$-60 Mil. Yichang HEC ChangJiang Pharmaceutical Co spent HK$60 Mil on other financial activities.


Yichang HEC ChangJiang Pharmaceutical Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Yichang HEC ChangJiang Pharmaceutical Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Yichang HEC ChangJiang Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN
Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Its products include Kewei, Ertongshu, Xinhaining, Oumeining and Xining.
Executives
Shao Guan Xin Yu Neng Shi Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Xiang Gang Dong Yang Guang Xiao Shou You Xian Gong Si 2101 Beneficial owner
Shen Zhen Shi Dong Yang Guang Shi Ye Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Guang Dong Dong Yang Guang Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Ru Yuan Yao Zu Zi Zhi Xian Xin Jing Ke Ji Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Ru Yuan Yao Zu Zi Zhi Xian Yu Neng Dian Zi Shi Ye You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Meilan 2201 Interest of corporation controlled by you
Hua Xiaoyi 2201 Interest of corporation controlled by you
Zhang Yushuai 2201 Interest of corporation controlled by you
Blackstone Dawn Pte. Ltd. 2101 Beneficial owner
Blackstone Tactical Opportunities Management Associates (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Inc. 2201 Interest of corporation controlled by you
Btof (dawn Feeder) (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Management Associates Iii (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Lr Associates (cayman) – Nq Ltd. 2201 Interest of corporation controlled by you

Yichang HEC ChangJiang Pharmaceutical Co Headlines

No Headlines